Abstract
Graft-versus-host disease (GVHD) is a severe complication of allogeneic stem cell transplantation. Donor T cells play major role in GVHD leading to the host tissue damage, mainly of the skin, liver, and gastrointestinal tract. T cell depletion leads to a decreasing risk of GVHD but also to an increasing risk of opportunistic infections, a relapse of the underlying disease, and a graft rejection. The selective depletion using an anti-CD25 immunotoxin can eliminate harmful alloreactive T cells while preserving other donor T cells with antileukemic and antibacterial reactivity. This review summarizes preclinical testing of the anti-CD25 immunotoxin performed by the authors and presents general characteristics of immunotoxins in anticancer therapy.
Translated title of the contribution | Prevention of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation using an anti-CD25 immunotoxin |
---|---|
Original language | Czech |
Pages (from-to) | 134-137 |
Number of pages | 4 |
Journal | Klinicka Onkologie |
Volume | 16 |
Issue number | 3 |
State | Published - 2003 |
Keywords
- Graft-versus-host disease
- Immunotoxin
- T cell
- Transplantation
ASJC Scopus subject areas
- Oncology